--- title: "Cytokinetics (CYTK) news: convertible notes and lawsuit" url: "https://aibio.space/companies/cytokinetics/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "CYTK convertible notes and lawsuit news: Cytokinetics issues $750.0 million of 1.75% convertible senior notes due 2031." --- CYTK Cytokinetics, Incorporated NASDAQ · United States # Cytokinetics (CYTK) news CYTK convertible notes and lawsuit news Legal · 2026-08-13 ## [Cytokinetics sues Bristol-Myers Squibb and MyoKardia in Delaware patent suit over MYQORZO](https://aibio.space/news/cytokinetics-sues-bristol-myers-squibb-myokardia-delaware-patent-suit/) Cytokinetics (Nasdaq: CYTK) filed a complaint on August 13, 2026, seeking a declaratory judgment that it does not infringe U.S. Patent No. 12,616,697 and that the patent's claims are invalid. The defendants are Bristol-Myers Squibb and MyoKardia. ## Latest Cytokinetics news 1. 2025-09-22 Debt Financing [Cytokinetics issues $750.0 million of 1.75% convertible senior notes due 2031](https://aibio.space/news/cytokinetics-issues-750-0-million-1-75-percent-convertible-senior/) Cytokinetics issued $750.0 million of 1.75% convertible senior notes due 2031 on September 19, 2025, and expects to spend about $402.5 million of the net proceeds on the cash side of exchanges for its 2027 notes. The notes convert at about $68.42 a share. Neither the 8-K nor the release gives the company's cash balance. ## Cytokinetics at a glance - **Ticker**: CYTK - **Listing**: NASDAQ - **Country**: United States - **Cash, Jun 30, 2026**: $1.17 billion ### Related companies - [REGENXBIO](https://aibio.space/companies/regenxbio/) NASDAQ: RGNX - [Retrieve Medical Holdings](https://aibio.space/companies/retrieve-medical/) OTC: RMHI - [Emmaus Life Sciences](https://aibio.space/companies/emmaus-life-sciences/) OTC: EMMA - [Alzamend Neuro](https://aibio.space/companies/alzamend-neuro/) NASDAQ: ALZN - [Amphastar Pharmaceuticals](https://aibio.space/companies/amphastar-pharmaceuticals/) NASDAQ: AMPH - [Pasithea Therapeutics](https://aibio.space/companies/pasithea-therapeutics/) NASDAQ: KTTA - [Bristol-Myers Squibb](https://aibio.space/companies/bristol-myers-squibb/) NYSE: BMY - [Metagenomi Therapeutics](https://aibio.space/companies/metagenomi-therapeutics/) NASDAQ: MGX ### Also on NASDAQ - [Pyxis Oncology](https://aibio.space/companies/pyxis-oncology/) PYXS - [Psyence Biomedical](https://aibio.space/companies/psyence-biomedical/) PBM - [Palisade Bio](https://aibio.space/companies/palisade-bio/) PALI - [AURORA CANNABIS INC](https://aibio.space/companies/aurora-cannabis/) ACB - [Crescent Biopharma](https://aibio.space/companies/crescent-biopharma/) CBIO - [Neuphoria Therapeutics](https://aibio.space/companies/neuphoria-therapeutics/) NEUP ## What Cytokinetics does Cytokinetics, Incorporated is a biopharmaceutical company focused on discovering, developing and commercializing muscle activators and muscle inhibitors for diseases in which muscle performance is compromised. Its first commercial product, MYQORZO (aficamten), was approved by the FDA in December 2025 for symptomatic obstructive hypertrophic cardiomyopathy (oHCM) in adults and became available for prescription on or around January 27, 2026. MYQORZO is an allosteric and reversible inhibitor of cardiac myosin motor activity, and its FDA approval includes a risk evaluation and mitigation strategy (REMS). The European Commission approved MYQORZO in February 2026, and China's National Medical Products Administration approved it in December 2025. The pipeline includes ACACIA-HCM, a Phase 3 trial evaluating aficamten in nHCM, and omecamtiv mecarbil, which is being evaluated in symptomatic heart failure with severely reduced ejection fraction in the COMET-HF study. Two earlier-stage candidates are ulacamten, for a subgroup of patients with symptomatic HFpEF with hypercontractility, and CK-089, with potential application to a specific type of muscular dystrophy. Cytokinetics has licensing agreements with Sanofi in China and Bayer in Japan. | Product or program | What it is | Stage | |---|---|---| | MYQORZO (aficamten) | Cardiac myosin inhibitor for symptomatic oHCM | approved by FDA, European Commission and China NMPA | | Aficamten in nHCM | Evaluated in the ACACIA-HCM trial | Phase 3 | | Omecamtiv mecarbil | Evaluated for symptomatic heart failure with severely reduced ejection fraction | | | Ulacamten | Candidate for a subgroup of patients with HFpEF with hypercontractility | clinical development | | CK-089 | Candidate for a specific type of muscular dystrophy | clinical development | Summarised from the company's [10-K filed Feb 26, 2026](https://www.sec.gov/Archives/edgar/data/1061983/000119312526076495/cytk-20251231.htm). ## Cytokinetics annual financials | Line | FY2025 | FY2024 | |---|---|---| | Research and development | [$416.0 million](https://www.sec.gov/Archives/edgar/data/1061983/000119312526076495/) | [$339.4 million](https://www.sec.gov/Archives/edgar/data/1061983/000119312526076495/) | | Net income (loss) | [-$785.0 million](https://www.sec.gov/Archives/edgar/data/1061983/000119312526076495/) | [-$589.5 million](https://www.sec.gov/Archives/edgar/data/1061983/000119312526076495/) | | Cash from operations | [-$510.0 million](https://www.sec.gov/Archives/edgar/data/1061983/000119312526076495/) | [-$395.9 million](https://www.sec.gov/Archives/edgar/data/1061983/000119312526076495/) | | Cash and equivalents | [$122.5 million](https://www.sec.gov/Archives/edgar/data/1061983/000119312526338217/) | [$94.9 million](https://www.sec.gov/Archives/edgar/data/1061983/000119312526076495/) | | Short-term investments | [$759.7 million](https://www.sec.gov/Archives/edgar/data/1061983/000119312526338217/) | [$981.2 million](https://www.sec.gov/Archives/edgar/data/1061983/000119312526076495/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $255.3 million, plus short-term investments of $910.4 million, $1.17 billion in all. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Cytokinetics Has Cytokinetics sold convertible notes? Our latest story on this, dated Sep 22, 2025: "Cytokinetics issues $750.0 million of 1.75% convertible senior notes due 2031". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/cytokinetics-issues-750-0-million-1-75-percent-convertible-senior/). Is Cytokinetics involved in a lawsuit? Our latest story on this, dated Aug 13, 2026: "Cytokinetics sues Bristol-Myers Squibb and MyoKardia in Delaware patent suit over MYQORZO". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/cytokinetics-sues-bristol-myers-squibb-myokardia-delaware-patent-suit/). What is the ticker symbol of Cytokinetics? Cytokinetics, Incorporated trades under the ticker CYTK on NASDAQ. Where is Cytokinetics listed? Cytokinetics, Incorporated is listed on NASDAQ. Our directory also records these other listings: DUS:KK3A; FWB:KK3A; GETTEX:KK3A; HAM:KK3A; HAN:KK3A; LS:A1W1KK; MUN:KK3A; SWB:KK3A; TRADEGATE:KK3A; XETR:KK3A. What is the SEC CIK of Cytokinetics? The SEC Central Index Key (CIK) for Cytokinetics, Incorporated is 1061983. Its filings are on SEC EDGAR. How many shares does Cytokinetics have outstanding? 139,023,418 shares as of 2026-08-04, per the cover page of its 10-Q filed 2026-08-06. Which country or territory is Cytokinetics listed under? Our directory records Cytokinetics, Incorporated under United States. What does Cytokinetics do? Our directory classifies Cytokinetics, Incorporated as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline. What is the ISIN of Cytokinetics? The ISIN recorded for Cytokinetics, Incorporated is US23282W6057. Does aibio.space cover Cytokinetics? aibio.space lists Cytokinetics, Incorporated among 2,820 public biotech companies and publishes its news here as stories appear. What does Cytokinetics develop? Cytokinetics, Incorporated is a biopharmaceutical company focused on discovering, developing and commercializing muscle activators and muscle inhibitors for diseases in which muscle performance is compromised. Its first commercial product, MYQORZO (aficamten), was approved by the FDA in December 2025 for symptomatic obstructive hypertrophic cardiomyopathy (oHCM) in adults and became available for prescription on or around January 27, 2026. What is MYQORZO (aficamten) from Cytokinetics? MYQORZO (aficamten): Cardiac myosin inhibitor for symptomatic oHCM Stage: approved by FDA, European Commission and China NMPA. What is Aficamten in nHCM from Cytokinetics? Aficamten in nHCM: Evaluated in the ACACIA-HCM trial Stage: Phase 3. Is Cytokinetics profitable? Cytokinetics, Incorporated reported a net loss of $785.0 million for the fiscal year ended Dec 31, 2025, and used $510.0 million of cash in operations, per its annual report to the SEC. How much does Cytokinetics spend on research and development? $416.0 million in the fiscal year ended Dec 31, 2025, per its annual report. ## Investor discussion: Cytokinetics Members talk about Cytokinetics (CYTK). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Cytokinetics, newest first. Each line links the filing it comes from. 1. 2026-05-27 Listings Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07). [Source](https://www.sec.gov/Archives/edgar/data/1061983/000119312526241840/cytk-20260527.htm) 2. 2026-05-05 Legal Disclosed a shareholder lawsuit, subpoena or other legal matter. SEC Form 10-Q. [Source](https://www.sec.gov/Archives/edgar/data/1061983/000119312526206364/cytk-20260331.htm) 3. 2026-05-05 Financings Set up an at-the-market program to sell shares over time. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1061983/000119312526206626/d127829d424b5.htm) 4. 2025-11-05 Legal Disclosed a shareholder lawsuit, subpoena or other legal matter. SEC Form 10-Q. [Source](https://www.sec.gov/Archives/edgar/data/1061983/000119312525267059/cytk-20250930.htm) 5. 2025-09-22 Financings Reported a financing. SEC Form 8-K (Items 1.01,2.03,3.02,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1061983/000119312525209437/d933506dex991.htm) 6. 2025-05-16 Listings Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07). [Source](https://www.sec.gov/Archives/edgar/data/1061983/000095017025072965/cytk-20250514.htm) 7. 2025-02-27 Financings Set up an at-the-market program to sell shares over time. SEC Form S-3ASR. [Source](https://www.sec.gov/Archives/edgar/data/1061983/000119312525039426/d778918ds3asr.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:CYTK on TradingView](https://www.tradingview.com/symbols/NASDAQ-CYTK/). ## SEC filings and registration - **SEC name**: Cytokinetics Inc - **CIK**: 1061983 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: CYTK (Nasdaq) - **Fiscal year ends**: December 31 - **Filer category**: Large accelerated filer - **Business address**: 350 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO, CA, 94080 - **Phone**: (650) 624-3000 - **Shares outstanding**: 139,023,418 as of 2026-08-04 (10-Q filed 2026-08-06) ### Recent filings (8-K and 6-K are the company's own announcements) - [8-K](https://www.sec.gov/Archives/edgar/data/1061983/000119312526372456/cytk-20260828.htm) filed 2026-08-28 - [8-K](https://www.sec.gov/Archives/edgar/data/1061983/000119312526348060/cytk-20260813.htm) filed 2026-08-13 - [10-Q](https://www.sec.gov/Archives/edgar/data/1061983/000119312526338217/cytk-20260630.htm) filed 2026-08-06 - [8-K](https://www.sec.gov/Archives/edgar/data/1061983/000119312526338021/cytk-20260806.htm) filed 2026-08-06 - [8-K](https://www.sec.gov/Archives/edgar/data/1061983/000119312526241840/cytk-20260527.htm) filed 2026-05-27 - [8-K](https://www.sec.gov/Archives/edgar/data/1061983/000119312526214606/d138544d8k.htm) filed 2026-05-08 - [424B5](https://www.sec.gov/Archives/edgar/data/1061983/000119312526212440/d127829d424b5.htm) filed 2026-05-07 - [424B5](https://www.sec.gov/Archives/edgar/data/1061983/000119312526206626/d127829d424b5.htm) filed 2026-05-05 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001061983), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Cytokinetics, Incorporated is a public biotech or pharmaceutical company listed on NASDAQ under the ticker CYTK, recorded under United States. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Cytokinetics, Incorporated - **Ticker**: CYTK - **Listing**: NASDAQ - **Country or territory**: United States - **Business scope**: Pharmaceuticals: Major - **ISIN**: US23282W6057 - **Other listed symbols**: DUS:KK3A; FWB:KK3A; GETTEX:KK3A; HAM:KK3A; HAN:KK3A; LS:A1W1KK; MUN:KK3A; SWB:KK3A; TRADEGATE:KK3A; XETR:KK3A - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-CYTK/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/cytokinetics/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Cytokinetics (CYTK) news: convertible notes and lawsuit", 2026-10-31, https://aibio.space/companies/cytokinetics/